We are a little bit on the road regarding funding with Budget 2022, although I want to point out—and this is one of the opportunities I think Health New Zealand really has. I'll use this as an example: a couple of years ago, there was a very strong push for devices to be purchased for type 1 diabetics to, effectively, keep them out of hospital. It was turned down and it was turned down because it was very, very narrow grounds for cost benefit, and yet the real benefit was going to be on the DHBs. This is the one thing I think that's good about this bill, because I don't think we're heading down the right road in terms of the restructure, but, actually, if Pharmac takes more cognisance of a broader range of benefits than just its own cost benefit, I think that'd be a good thing.